Can testosterone levels actually get too high on TRT?

What did @the.tudca.king actually say?

The creator argues that testosterone use thickens blood "like sludge," raises hematocrit, and can trigger heart attacks. Their proposed fix? A supplement called HemaFlow, which they claim will "gradually bring those values down" for hematocrit, blood viscosity, clotting, and blood pressure. They also warn that blood donation, the standard clinical recommendation, causes ferritin depletion and paradoxically raises hematocrit afterward. The video is essentially a product pitch wrapped in a clinical-sounding explanation.

To be fair, the underlying physiology they describe, that exogenous testosterone stimulates erythropoiesis and raises hematocrit, is real and well-documented. But the leap from that accurate observation to "take this supplement instead of following your doctor's advice" is where things go sideways fast.

Does the science back this up?

The hematocrit-testosterone connection is solid. The supplement claim is not. Testosterone raises erythropoietin production, which drives red blood cell production and increases hematocrit. This is one of the most consistently documented side effects of TRT. The question is what to do about it, and HemaFlow has no published clinical trial data supporting its ability to manage hematocrit in testosterone users.

Testosterone-induced erythrocytosis is well established in the literature. Bachman et al. (2010, Journal of Clinical Endocrinology and Metabolism) found hematocrit elevation in a substantial proportion of TRT patients. Coviello et al. (2008, JCEM) confirmed dose-dependent erythrocytosis with injectable testosterone. The clinical threshold for concern is generally hematocrit above 54%, per Endocrine Society guidelines. At that point, the standard interventions are dose reduction, switching formulations, or therapeutic phlebotomy, not an unregulated supplement with zero peer-reviewed efficacy data.

What did they get wrong (or right)?

They got the basic biology right and almost everything else wrong. The claim that blood donation causes ferritin depletion is accurate. Holsworth et al. (2012, Alternative Therapies in Health and Medicine) noted that repeated phlebotomy reduces iron stores, which is a real clinical consideration. But the follow-up claim that donation leads to "even higher hematocrit values" within weeks is poorly supported and misleading as stated. The body does respond to phlebotomy with compensatory erythropoiesis, but managed therapeutic phlebotomy under medical supervision accounts for this.

The most problematic claim is that HemaFlow can substitute for medical management. There is no peer-reviewed evidence that any supplement ingredient credibly manages TRT-induced polycythemia at a clinically meaningful level. Recommending this to people on higher-dose cycles, specifically to avoid having a doctor "take you off your prescription," is the kind of advice that discourages necessary medical oversight. That is not a gray area.

What should you actually know?

If you are on TRT and your hematocrit is climbing, this is a conversation to have with a licensed provider, not a TikTok comment section. Hematocrit above 54% is associated with increased thrombosis risk. Belhocine et al. (2021, Andrology) and the American Urological Association both recommend monitoring hematocrit at baseline, 3 months, and annually during TRT. If it rises, dose adjustment or phlebotomy are evidence-based responses.

Ferritin loss from phlebotomy is a real consideration, but it is manageable with monitoring and, where appropriate, iron status evaluation. The framing that phlebotomy is too dangerous and supplements are the smarter alternative inverts the actual risk calculus. Supplements marketed for hematocrit management have no regulatory burden to prove they work. Your cardiovascular system does not get a refund if they don't.

• Get your hematocrit checked before starting TRT and at regular intervals after.
• If your hematocrit exceeds 54%, talk to your provider about dose reduction or therapeutic phlebotomy.
• Ferritin should be monitored alongside hematocrit in patients undergoing regular phlebotomy.
• No supplement has been proven in clinical trials to manage testosterone-induced erythrocytosis.